AYTU BioPharma, Inc. (AYTU) Q1 2024 Earnings
AYTU·Reported May 15, 2024·After market close
AYTU BioPharma, Inc. reported Q1 2024 revenue of $18.0M, missed analyst consensus of $18.3M by $307.0K. Diluted EPS came in at $-0.52, beat the $-0.64 consensus by $0.12.
Revenue
$18.0Mmissed by $307.0K
Consensus: $18.3MDiluted EPS
$-0.52beat by $0.12
Consensus: $-0.64
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about AYTU BioPharma, Inc.'s Q1 2024 earnings report.
AYTU BioPharma, Inc. (AYTU) reported Q1 2024 earnings on May 15, 2024 after market close.
AYTU BioPharma, Inc. reported revenue of $18.0M and diluted EPS of $-0.52 for Q1 2024.
Revenue missed the consensus estimate of $18.3M by $307.0K. EPS beat the consensus estimate of $-0.64 by $0.12.
You can read the 10-Q periodic report (0001437749-24-017051) directly on SEC EDGAR. The filing index links above go to sec.gov.